

Immunoglobulin Deficiencies: The B-Lymphocyte Side of DiGeorge Syndrome

Kiran Patel, MD¹, Javeed Akhter, MD², Lisa Kobrynski, MD, MPH³, Benjamin Gathman, MA⁴, Onika Davis, BS⁵, and Kathleen E. Sullivan, MD, PhD¹, on behalf of the International DiGeorge Syndrome Immunodeficiency Consortium*

DiGeorge syndrome is associated with a T-lymphocyte immunodeficiency. The prevalence of hypogammaglobulinemia has not been reported. We found that 3% of patients with DiGeorge syndrome were receiving immunoglobulin replacement therapy and 6% of patients over the age of 3 years had hypogammaglobulinemia. We conclude that DiGeorge syndrome is associated with significant humoral immune deficiency. (*J Pediatr* 2012;161:950-3).

DiGeorge syndrome is a common syndrome occurring in approximately 1:3000 births. It is a clinical constellation of findings united by a common embryologic origin associated with cardiac anomalies, parathyroid gland hypoplasia, and thymus hypoplasia or aplasia.^{1,2} Many infants have been found to have low circulating T-lymphocyte counts, with some improvement over the first year of life.³ Not all T-lymphocyte subsets are affected equally by thymic hypoplasia, in part due to homeostatic expansion.^{4,5}

A series of studies have hinted that humoral immunity may not be robust in patients with DiGeorge syndrome.⁶⁻⁸ There have been case reports of patients who appeared to have common variable immunodeficiency,⁹⁻¹¹ immunoglobulin A (IgA) deficiency, immunoglobulin M (IgM) deficiency, and impaired vaccine response.^{8,12,13} One study showed delayed B-lymphocyte maturation manifested with lower naïve and unswitched memory B lymphocyte.⁴ Another study showed decreased memory B lymphocytes.¹² To better characterize humoral immunity in DiGeorge syndrome, we examined immunoglobulin levels in an international cohort of 1023 patients with DiGeorge syndrome.

Methods

The United States Immunodeficiency Network (USIDNET) and the European Society for Immunodeficiencies (ESID) registries and members were queried for cases categorized as DiGeorge syndrome. Both registries enroll patients with velocardiofacial syndrome and chromosome 22q11.2 deletion syndrome under the same umbrella designation. Members of the Latin American Society for Immunodeficiencies were sent an e-mail requesting their support of the same study. Data from 21 countries and 40 different contributors

were compiled; 662 records were obtained from USIDNET, 381 from ESID, 327 from the Children's Hospital of Philadelphia, and fewer than 50 patients per institution from the remaining contributors. USIDNET and ESID collected information from subjects who consented for the study. The remainder of the patients' data were collected in an anonymous fashion in accordance with the local regulatory guidelines at each institution. Duplicate patients were removed manually and the final evaluable subject count was 1023. For patients with data from multiple points in time, data from the oldest age were utilized. Correlation coefficients were calculated using the Pearson method and linear regression analyses were performed within Prism. We defined a low serum immunoglobulin G (IgG) value as <500 mg/dL and a low CD3⁺ count as <500 cells/mm³ to stratify patients for the Pearson analysis. All *P* values were computed as 2-tailed *P* values.

Results

This cohort consisted of 1023 patients with DiGeorge syndrome. The mean age was 5.5 years and the median age was 3.0 years; 855 patients had immunoglobulin data available. Responses to vaccines were not available for most subjects; 42% of the cohort were identified as having a chromosome 22 deletion. For the remainder, no genetic basis was recorded.

We examined immunoglobulin levels according to age. The normal ranges are shown in grey in **Figure 1**. For the association of IgG, A, and M with age, the direct correlation coefficient was mild to moderate for IgG ($r = 0.4516$, $P < .0001$) and IgA ($r = 0.2828$, $P < .0001$); however, IgM levels

ESID	European Society for Immunodeficiencies
IgA	Immunoglobulin A
IgG	Immunoglobulin G
IGIV	Immunoglobulin intravenous
IgM	Immunoglobulin M
USIDNET	United States Immunodeficiency Network

From the ¹Division of Allergy Immunology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; ²Division of Pediatric Pulmonology Advocate Christ Medical Center, Oak Lawn, IL; ³Division of Allergy Immunology, Emory Children's Center, Atlanta, GA; ⁴European Society for Immunodeficiencies Registry Working Party Centre of Chronic Immunodeficiency, University Medical Center Freiburg, and University of Freiburg, Freiburg, Germany; and ⁵United States Immunodeficiency Network Registry, Towson, MD

*A list of members of the International DiGeorge Syndrome Immunodeficiency Consortium is available at www.jpeds.com (**Appendix**).

K.S. and B.G. receive salary support from the registries that hold the data that was extracted for this analysis. The authors declare no conflicts of interest.

0022-3476/\$ - see front matter. Copyright © 2012 Mosby Inc.
All rights reserved. <http://dx.doi.org/10.1016/j.jpeds.2012.06.018>




Figure 1. Immunoglobulin levels expressed as a function of age. **A**, IgG, **B**, IgA, and **C**, IgM levels are plotted according to the age in patients with DiGeorge syndrome. *Black line* indicates the trend and the *grey lines* represent the 95% CI for published normative data.¹⁵ For each class of immunoglobulin, there are outliers both on the high and low end of the spectrum.

had no significant correlation with age ($r = 0.3831$, $P = .4283$) (Figure 1). We further evaluated immunoglobulin levels at older ages to exclude transient hypogammaglobulinemia of infancy. IgG and IgA levels had a moderate direct association with age for those over 3 years ($r = 0.2694$, 0.3615 ; $P < .0001$, $<.0001$ respectively). IgG levels also correlated with age for ages greater than 5 years ($r = 0.1918$, $P = .0004$). IgM levels did not correlate for ages greater than 3 years ($r = 0.01$, $P = .8317$).

We assessed associations between $CD3^+$ counts and immunoglobulin levels (Figure 2). The inverse correlation between age and $CD3^+$ count was moderate ($r = -0.2543$, $P < .001$). There was a weak association between $CD3^+$ count and IgG levels ($r = -0.1071$, $P < .0084$). We assessed IgG levels associated with low $CD3^+$ count ($CD3^+$ count <500 cells/ mm^3) and found no clear association

($r = 0.005331$, $P = .9754$). Analysis of low IgG levels (IgG <500 mg/dL) and $CD3^+$ count also showed no clear association ($r = -0.07630$, $P = .4414$). We similarly explored potential associations between $CD3^+$ count and IgA or IgM levels but found no association (data not shown).

A total of 2.7% (28 total) of the patient cohort was receiving immunoglobulin intravenous (IGIV) replacement therapy, with a broad age range of 2 months-17 years. A total of 3% of patients over the age of 3 years were receiving IGIV. The mean $CD3^+$ count was 1210 cells/ mm^3 for patients receiving IGIV (range 130-4310 cells/ mm^3). The mean IgG, A and M levels were 832 mg/dL, 77 mg/dL, and 103 mg/dL (ranges: 181-1740 mg/dL, 5-257 mg/dL, and 22-649 mg/dL, respectively). The registry data did not include information on whether the IgG levels were obtained on or off immunoglobulin replacement or treatment, however, we were able to analyze immunoglobulin levels and $CD3^+$ counts for the 28 subjects receiving immunoglobulin replacement and compare them with subjects not receiving immunoglobulin replacement therapy. Neither age, IgG, IgA, IgM, or $CD3^+$ count differed significantly between the 2 groups. Of the 28 subjects receiving immunoglobulin replacement, 9 were under 3 years of age. Of the 19 subjects over 3 years of age, 4 patients had an IgG <500 mg/dL.

Overall, 19% (150 total) of patients had IgG levels less than 500 mg/dL; 6.2% (28 total) of patients over the age of 3 and 5.6% (19 total) over the age of 5 years had levels of IgG <500 mg/dL. A total of 7 patients had undetectable IgA levels (IgA = 0 mg/dL); ages ranged from 4-15 years with the mean age of 8.7 years. A total of 10 patients (1.3%) had measurable levels below 5 mg/dL; all were greater than 3 years of age. 27% of patients (216 total) had IgM levels below 40 mg/dL; 23% (104 total) of patients greater than 3 years of age had IgM levels <40 mg/dL. Elevated IgG, IgA, and IgM levels were seen as well and we noted that these were observed primarily in the younger children.

Discussion

DiGeorge syndrome classically has been thought to be a T-lymphocyte disorder, however, recurrence and severity of infections have not always correlated with T-lymphocyte number.^{8,14} There is now a growing body of evidence that B-lymphocyte functional deficit and hypogammaglobulinemia are associated with more severe infections in this syndrome,⁸ thus, warranting more attention.

Our study is the largest report to date of immunoglobulin levels in this patient population. We showed that low levels of immunoglobulin are present in a significant minority of patients, and overall, between 2% and 3% of patients were receiving immunoglobulin replacement therapy. This study has several limitations imposed by the registry approach. The definition of DiGeorge syndrome was not uniform. Data sets were incomplete. There could be ascertainment bias due to the immunologic orientation of these registries and the data submitters. However, this study includes the largest collection of data on patients with DiGeorge




Figure 2. T-lymphocyte counts in patients with DiGeorge syndrome. These analyses express the CD3⁺ T-lymphocyte count according to **A**, age and **B**, the IgG level according to the CD3⁺ count. **A**, The expected age-dependent decrease in CD3⁺ counts. There are no associations between CD3⁺ counts and IgG levels in general or in those with lower levels of either (**C**, data for patients with low CD3⁺ counts and **D**, those with low IgG).

syndrome and a registry approach is a valuable strategy to investigate features that are present in a small subset of patients.

There are multiple areas for further investigation including a better understanding of the indications for immunoglobulin therapy in these patients and how best to provide antimicrobial support for patients. Also, it would be useful to determine the impact of immunoglobulin replacement on the infection pattern. This study demonstrates the need for collaboration between groups to identify medically significant features present in a minority of patients. Although imperfect, a registry approach in this case revealed an unexpectedly high frequency of humoral immune deficiency. Greater attention to the humoral component of the immune deficiency could lead to additional beneficial therapies. Patients should be evaluated with this in mind.⁸ Lacking comparative effectiveness data, a specific recommendation for evaluation can at best be considered tentative. One strategy would be to measure IgG, IgA, IgM levels; and diphtheria and tetanus titers in immunized patients, with recurrent sinopulmonary infections and to offer either prophylactic antibiotics or immunoglobulin replacement when humoral immunity is judged to be insufficient to provide protection. ■

The authors wish to thank the registry staff, nurses, trainees, and other staff who have supported these registry efforts. The ESID database is funded by the Plasma Protein Therapeutics Association.

Submitted for publication Feb 28, 2012; last revision received May 17, 2012; accepted Jun 7, 2012.

Reprint requests: Kathleen E. Sullivan, Division of Allergy Immunology, The Children's Hospital of Philadelphia, 3615 Civic Center Blvd. Philadelphia, PA 19104. E-mail: sullivak@mail.med.upenn.edu

References

1. DiGeorge AM. Discussions on a new concept of the cellular basis of immunology. *J Pediatr* 1965;67:907.
2. DiGeorge AM. Congenital absence of the thymus and its immunological consequences: concurrence with congenital hypothyroidism. *Birth Defects* 1968;4:116-21.
3. Sullivan KE, McDonald-McGinn D, Driscoll D, Emanuel BS, Zackai EH, Jawad AF. Longitudinal analysis of lymphocyte function and numbers in the first year of life in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). *Clin Diagn Lab Immunol* 1999;6:906-11.
4. McLean-Tooke A, Barge D, Spickett GP, Gennery AR. Immunologic defects in 22q11.2 deletion syndrome. *J Allergy Clin Immunol* 2008;122:362-7. 7 e1-4.
5. Sullivan KE, McDonald-McGinn D, Zackai EH. CD4(+) CD25(+) T-cell production in healthy humans and in patients with thymic hypoplasia. *Clin Diagn Lab Immunol* 2002;9:1129-31.
6. Junker AK, Driscoll DA. Humoral immunity in DiGeorge syndrome. *J Pediatr* 1995;127:231-7.
7. Zemle R, Luning Prak E, McDonald K, McDonald-McGinn D, Zackai E, Sullivan K. Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). *Clin Immunol* 2010;136:409-18.
8. Gennery AR, Barge D, O'Sullivan JJ, Flood TJ, Abinun M, Cant AJ. Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome. *Arch Dis Child* 2002;86:422-5.
9. Boyle M, Scalchunes C. Impact of intravenous immunoglobulin (IVIG) treatment among patients with primary immunodeficiency diseases. *Pharm Policy Law* 2008;10:133-46.

10. MacLeish S, Hostoffer R. Subcutaneous versus intravenous immunoglobulin for the treatment of DiGeorge syndrome related hypogammaglobulinemia. *J Allergy Clin Immunol* 2006;117(Suppl):S174.
11. Chien YH, Yang YH, Chu SY, Hwu WL, Kuo PL, Chiang BL. DiGeorge sequence with hypogammaglobulinemia: a case report. *J Microbiol Immunol Infect* 2002;35:187-90.
12. Finocchi A, Di Cesare S, Romiti ML, Capponi C, Rossi P, Carsetti R, et al. Humoral immune responses and CD27+ B cells in children with DiGeorge syndrome (22q11.2 deletion syndrome). *Pediatr Allergy Immunol* 2006;17:382-8.
13. Smith CA, Driscoll DA, Emanuel BS, McDonald-McGinn DM, Zackai EH, Sullivan KE. Increased prevalence of immunoglobulin A deficiency in patients with the chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). *Clin Diagn Lab Immunol* 1998;5:415-7.
14. Sullivan KE, Jawad AF, Randall P, Driscoll DA, Emanuel BS, McDonald-McGinn DM, et al. Lack of correlation between impaired T cell production, immunodeficiency and other phenotypic features in chromosome 22q11.2 deletions syndrome (DiGeorge syndrome/velocardiofacial syndrome). *Clin Immunol Immunopathol* 1998;84:141-6.
15. Jolliff CR, Cost KM, Stivrins PC, Grossman PP, Nolte CR, Franco SM, et al. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. *Clin Chem* 1982;28:126-8.

Appendix

Members of the International DiGeorge Syndrome Immuno-deficiency Consortium include:

European Society for Immunodeficiencies members:

Bernd H. Belohradsky, Kirsten Bienemann, Fabiola Carac-seghi, Peter Ciznar, Evangelia Farmaki, Andrew Gennery, Luis Ignacio Gonzalez Granado, Sara Sebnem Kilic, Viviane Knerr, Necil Kutukculer, Laura Marques, Isabelle Meyts, Malgorzata Pac, Efimia Papadopoulou-Alataki, Shereen Reda, Janine Reichenbach, Henrike Ritterbusch, Juan Luis Santos, Anna Sediva, Markus Seidel, Anna Shcherbina, Olesya Shvets, Anna Szaflarska, Sirje Velbri, Olcay Yegin

Latin American Society for Immunodeficiencies members:

Gabriela Belardinelli, Liliana Bezrodnik, Magda Carneiro-Sampaio, Daniella diGiovanni, Isabel Gaillard, Andrea Gomez Raccio, Ekaterini Goudouris

United States Immunodeficiency Network members:

Javeed Akhter, Francisco Bonilla, Laurence Cheng, Charlotte Cunningham Rundles, Vivian Henandez-Trujillo, Lisa Kobrynski, Mica Muscat, Jennifer Puck, Kathleen Sullivan